CoChat

Ivabradine in Patients with ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock: A Preliminary Randomized Prospective Study

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background and objective An elevated heart rate (HR) is an independent risk factor for mortality and morbidity in patients with acute heart failure (HF). The purpose of this study was to evaluate the impact of ivabradine, a selective HR-lowering agent, in patients with cardiogenic shock (CS) complicating ST-elevation acute myocardial infarction (AMI). Methods Patients with post-AMI CS were randomized to standard treatment (SDT, 28 patients) or to standard treatment plus ivabradine (I + SDT, 30 patients). In the presence of orotracheal intubation (OTI), ivabradine was administered by nasogastric intubation. HR, BP, New York Heart Association (NYHA) class, NT-proBNP, left ventricular ejection fraction (LVEF) and diastolic function (LVDF) were monitored at specific times after the onset of AMI. The primary (surrogate) end-point was the in-hospital halving of plasma NT-proBNP levels. The secondary end-points were cardiovascular death, hospital re-admission for worsening HF, and clinical and haemodynamic improvement. Results Treatment groups were statistically similar with regard to age, gender distribution, cardiovascular risk factors, number of diseased vessels and overall treated lesions, AMI site and occurrence of OTI. In-hospital mortality was double in the SDT group in comparison with the I + SDT group (14.3 vs. 6.7 %), but the difference was not statistically significant. HR, BP, NT-proBNP and LVEF favorably changed in both groups, but the change was more relevant in the I…

Overview

Integrity signals

Registry

Crossref · 10.1007/s40261-016-0424-9

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

See all 51

Metadata

Authors
Barillà, F., Pannarale, G., Torromeo, C., Paravati, V., Acconcia, M. C., Tanzilli, G., Mangieri, E., Dominici, T., Martino, F., Pannitteri, G., & Gaudio, C.
Affiliations
Sapienza University of Rome (IT)
Corresponding author
Barillà, Francesco
Venue
Clinical Drug Investigation
Published
2016-06-16
Volume
36
Issue
10
Pages
849-856
ISSN
  • 0114-2402 (ISSN-L)
  • 1173-2563
  • 1179-1918
OpenAlex
W2425075297
Cited by
51
References
17
Citations by year
2026: 1 · 2025: 8 · 2024: 10 · 2023: 1 · 2022: 6 · 2021: 9 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 2
FWCI
2.08
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Drug Investigation (publishedVersion)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Mechanical Circulatory Support Devices
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
ivabradine, cardiogenic shock, ST-elevation myocardial infarction, heart rate reduction, NT-proBNP, left ventricular diastolic function, in-hospital mortality, acute heart failure, nasogastric tube insertion, left ventricular ejection fraction
MeSH terms
ST Elevation Myocardial Infarction, Ivabradine, Acute Disease, Adult, Aged, Benzazepines, Cardiovascular Agents, Female, Heart Failure, Humans, Male, Middle Aged, Peptide Fragments, Prospective Studies, Risk Factors, Shock, Cardiogenic, Ventricular Function, Left, Natriuretic Peptide, Brain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ivabradine in Patients with ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock: A Preliminary Randomized Prospective Study. https://app.cochat.ai/papers/10.1007/s40261-016-0424-9
The paper
Barillà, F., Pannarale, G., Torromeo, C., Paravati, V., Acconcia, M. C., Tanzilli, G., Mangieri, E., Dominici, T., Martino, F., Pannitteri, G., & Gaudio, C. (2016). Ivabradine in Patients with ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock: A Preliminary Randomized Prospective Study. Clinical Drug Investigation. https://doi.org/10.1007/s40261-016-0424-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.